10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Amendment No. 1

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2015
¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from                           to                           .

Commission File number 000-00935

MEDITE CANCER DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	36-4296006
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
4203 SW 34th Street, Orlando, FL	32811
(Address of principal executive offices)	(Zip Code)

(407) 996-9630

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
None	Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨ (not required) ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rue 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ¨	Accelerated Filer ¨
Non-Accelerated Filer ¨	Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

COMMON STOCK, $0.001 PAR VALUE, AT May 20, 2015: 19,679,956

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to Medite Cancer Diagnostics, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015, filed with the Securities and Exchange Commission on May 20, 2015 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to the Form 10-Q provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (Extensible Business Reporting Language).

No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

Item 6. Exhibits

Exhibit
Number	Description
31.1*	Section 302 certification by the principal executive officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
31.2*	Section 302 certification by the chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1*	Section 906 certification by the principal executive pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
32.2*	Section 906 certification by the chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS*	XBRL Instance
101.SCH*	XBRL Taxonomy Extension Schema
101.CAL*	XBRL Taxonomy Extension Calculation
101.DEF*	XBRL Taxonomy Extension Definition
101.LAB*	XBRL Taxonomy Extension Labels
101.PRE*	XBRL Taxonomy Extension Presentation

* Filed with this Amendment No. 1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDITE Cancer Diagnostics, Inc.
Date:  May 21, 2015	/s/ Michaela Ott
	Michaela Ott
	Chief Executive Officer
Date: May 21, 2015	/s/ Robert F. McCullough, Jr.
	Robert F. McCullough, Jr.
	Chief Financial Officer

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Michaela Ott, certify that:

(1)	I have reviewed this quarterly report on Form 10-Q of MEDITE Cancer Diagnostics, Inc.;
(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
(5)	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michaela Ott

Michaela Ott

Chief Executive Officer

Dated:  May 21. 2015

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Robert F. McCullough Jr., certify that:

(1)	I have reviewed this quarterly report on Form 10-Q of MEDITE Cancer Diagnostics, Inc.;
(2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
(5)	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Robert F. McCullough Jr.

Robert F. McCullough Jr.

Chief Financial Officer

Dated:  May 21, 2015

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MEDITE Cancer Diagnostics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission (the “Report”), I, Michaela Ott, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition as of the dates presented and the results of operations of the Company for the periods presented.

/s/ Michaela Ott

Michaela Ott

Chief Executive Officer

Dated:  May 21, 2015

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MEDITE Cancer Diagnostics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission (the “Report”), I, Robert McCullough, Jr., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition as of the dates presented and the results of operations of the Company for the periods presented.

/s/ Robert F. McCullough, Jr.

Robert F. McCullough, Jr.

Chief Financial Officer

Dated:  May 21, 2015

XML

Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) (Warrants and Stock Options [Member], USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrants and Stock Options [Member]
Options and Warrants, Opening Balance	143,308
Options and Warrants, Granted	0
Options and Warrants, Exercised	0
Options and Warrants, Expired	0
Options and Warrants, Ending Balance	143	143,308
Weighted Average Exercise Price, Opening Balance	$ 2.64
Weighted Average Exercise Price, Granted	$ 0
Weighted Average Exercise Price, Exercised	$ 0
Weighted Average Exercise Price, Expired	$ 0
Weighted Average Exercise Price, Ending Balance	$ 2.64	$ 2.64
Aggregate Intrinsic Value, Opening Balance	$ 0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Ending Balance	$ 0	$ 0
Weighted Average Remaining Contractual Life(Years),Outstanding	6 years 5 months 16 days	6 years 5 months 16 days
Warrants Outstanding Granted Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Exercised Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Expired Weighted Average Remaining Contractual Term	0 years

XML

Related Party Advances - Additional Information (Detail) (USD $)	0 Months Ended
	May 15, 2015	Mar. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Due To Related Parties Current		$ 1,060,000	$ 110,000
Subsequent Event [Member]
Related Party Transaction [Line Items]
Due To Related Parties Current	330,000
CFO and Chairman of BOD [Member]
Related Party Transaction [Line Items]
Due To Related Parties Current			110,000
CEO and COO [Member]
Related Party Transaction [Line Items]
Due To Related Parties Current		950,000
Officer [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Repayments of Other Short-term Debt	$ 620,000

XML

Organization and Summary of Significant Accounting Policies - (Additional Information) (Detail)	Mar. 31, 2015	Dec. 31, 2014	Apr. 30, 2014
Business Acquisition [Line Items]
Common Stock, Shares, Outstanding	19,679,956	19,427,331
Common Stock, Shares, Issued	19,679,956	19,427,331
Medite Enterprise [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Common Stock, Shares, Outstanding			14,687,500
Common Stock, Shares, Issued			14,687,500

XML

Segment Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Assets	$ 16,858		$ 16,439
Property & equipment, net	2,002		2,091
Intangible Assets	8,313		8,313
Revenues	2,287	2,734
Net income (loss)	(255)	219
United States [Member]
Segment Reporting Information [Line Items]
Assets	9,307		9,387
Property & equipment, net	99		98
Intangible Assets	8,313		8,313
Revenues	280	157
Net income (loss)	(163)	19
Germany [Member]
Segment Reporting Information [Line Items]
Assets	7,449		6,989
Property & equipment, net	1,896		1,985
Intangible Assets	0		0
Revenues	2,003	2,577
Net income (loss)	(76)	200
Poland [Member]
Segment Reporting Information [Line Items]
Assets	102		63
Property & equipment, net	7		8
Intangible Assets	0		0
Revenues	4	0
Net income (loss)	$ (16)	$ 0

XML

Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred Stock, Liquidation Value	$ 1,121	$ 2,871
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Value	212,625
Preferred Stock, Conversion Price	$ 10,303
Preferred stock, conversion Rate	0.00044%
Preferred stock, voting Rights	None
Preferred Stock, Conversion Period	Any time
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Value	375,000
Preferred Stock, Conversion Price	$ 1,000
Preferred stock, conversion Rate	0.004%
Preferred stock, voting Rights	None
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred stock, cumulative and undeclared dividends in arrears	530,038	520,665
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Value	115,000
Preferred Stock, Conversion Price	$ 600
Preferred stock, conversion Rate	0.005%
Preferred stock, voting Rights	None
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred stock, cumulative and undeclared dividends in arrears	154,288	151,413
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Dividends	10.00%	10.00%
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Value	418,488
Preferred Stock, Conversion Price	$ 800.00
Preferred stock, conversion Rate	0.0275%
Preferred stock, voting Rights	Equal in all respects to holders of common shares
Preferred Stock, Dividends	10.00%	10.00%
Preferred Stock, Conversion Period	Any time
Preferred stock, cumulative and undeclared dividends in arrears	$ 568,177	$ 558,173

XML

Property and Equipment

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 4. Property and Equipment

The following is a summary of the components of property and equipment (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Land	$	208	$	233
Buildings		1,152		1,291
Machinery and equipment		492		529
Office furniture and equipment		237		265
Vehicles		92		103
Computer equipment		106		110
Construction in progress		510		559
Less: Accumulated depreciation		(795)		(999)
	$	2,002	$	2,091

Depreciation expense amounted to approximately $34,000 and $62,000 for the three months ended March 31, 2015 and 2014, respectively.

XML

Segment Information - (Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Foreign Currency Exchange Rate Translation Amount	$ 0.47	$ 0.47

XML

Property and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Land	$ 208	$ 233
Buildings	1,152	1,291
Machinery and equipment	492	529
Office furniture and equipment	237	265
Vehicles	92	103
Computer equipment	106	110
Construction in progress	510	559
Less: Accumulated depreciation	(795)	(999)
Total	$ 2,002	$ 2,091

XML

Inventories - (Summary of the Components of Inventories) (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 1,208	$ 1,229
Work in progress	27	33
Finished Goods	1,940	2,153
Inventory, Net	$ 3,175	$ 3,415

XML

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 34,000	$ 62,000

XML

Long-term Debts and Lines of Credit (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 3,424	$ 3,764
Hannoversech Volksbank Credit line 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	1,787	1,880
Hannoversech Volksbank Credit line 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	409	465
Hannoversech Volksbank term loan 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	93	135
Hannoversech Volksbank term loan 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	74	81
Hannoversech Volksbank term loan 3 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	226	270
Ventana Medical Systems, Inc. Promissory Note [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	21	21
Debenture DZ Equity Partners Participation rights
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 814	$ 912

XML

Inventories

3 Months Ended

Mar. 31, 2015

Inventory Disclosure [Abstract]

Inventories

Note 3. Inventories

The following is a summary of the components of inventories (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Raw materials	$	1,208	$	1,229
Work in progress		27		33
Finished Goods		1,940		2,153
	$	3,175	$	3,415

No amounts were reserved for obsolete inventory as of March 31, 2015 and December 31, 2014.

XML

Long-term Debts and Lines of Credit - Additional Information (Detail)						3 Months Ended								3 Months Ended										1 Months Ended
	Mar. 31, 2015 Participation Rights Agreement In March 2009 [Member] EUR (€)	Mar. 31, 2015 Participation Rights Agreement In March 2009 [Member] Tranche One [Member] EUR (€)	Mar. 31, 2015 Participation Rights Agreement In March 2009 [Member] Tranche Two [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] USD ($)	Dec. 31, 2012 Medite GmbH, Burgdorf [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] EUR (€)	Jan. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Maximum [Member]	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Minimum [Member]	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Subsequent Event [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 2 Issued in July 2006 [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 2 Issued in July 2006 [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 1 Issued in December 2006 [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 1 Issued in December 2006 [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 2 Issued in June 2006 [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 2 Issued in June 2006 [Member] EUR (€)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 3 Issued in November 2008 [Member] USD ($)	Mar. 31, 2015 Medite GmbH, Burgdorf [Member] Hannoversech Volksbank term loan 3 Issued in November 2008 [Member] EUR (€)	Mar. 31, 2015 CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] USD ($)	Mar. 31, 2015 CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] EUR (€)	Mar. 31, 2015 CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] Maximum [Member]	Mar. 31, 2015 CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] Minimum [Member]	Feb. 23, 2015 Ventana Medical Systems, Inc [Member] USD ($)	Mar. 31, 2015 Ventana Medical Systems, Inc [Member] USD ($)
Line of Credit Facility [Line Items]
Debt instrument face amount	€ 1,500,000	€ 750,000	€ 750,000											$ 542,500	€ 500,000	$ 434,000	€ 400,000	$ 434,000	€ 400,000
Debt Instrument, Interest Rate, Stated Percentage	12.15%								8.00%	3.77%				3.40%	3.40%	3.60%	3.60%	4.70%	4.70%			8.00%	3.77%
Principal repayments														30,141	27,780	24,109	22,220	15,071	13,890
Line of Credit Facility, Maximum Borrowing Capacity				2,000,000	1,800,000			1,600,000			1,700,000	1,200,000	1,100,000
Line of Credit Facility, Increase (Decrease), Net						542,505	500,000
Notes Payable, Current																									21,000
Repayments of Debt																								38,281
Dividends Payable, Current																								656,250
Agreed To Convert Of Preferred Stock For Common Stock																								1,750,000
Number Of Stock To Be Converted From Preferred Stock																								12,000
Line of Credit Facility, Current Borrowing Capacity																				$ 434,000	€ 400,000

XML

Preferred Stock and Warrants (Additional Information) (Detail) (USD $)	1 Months Ended
	Feb. 23, 2015
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 175,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	12,000
Series D Preferred Stock [Member]
Dividends Payable, Current	$ 656,250

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equvalents	$ 1,026	$ 230
Accounts receivable	1,833	1,991
Inventories	3,175	3,415
Prepaid expenses and other current assets	94	154
Total current assets	6,128	5,790
Property and equipment, net	2,002	2,091
In-process research and development	4,620	4,620
Trademarks, trade names	1,240	1,240
Goodwill	2,453	2,453
Other assets	415	245
Total assets	16,858	16,439
Current liabilities:
Secured lines of credit and current portion of long-term debt	2,392	2,555
Account payable and accrued expenses	4,088	4,134
Advances - related parties	1,060	110
Total current liabilities	7,540	6,799
Long-term debt, net of current portion	1,032	1,209
Total liabilities	8,572	8,008
Commitments and contingencies
Stockholders’ equity :
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 and 373,355 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively (liquidation value of all classes of preferred stock $1,121 and $2,871 as of March 31, 2015 and December 31, 2014, respectively)	962	1,487
Common stock, $0.001 par value; 3.5 billion shares authorized, 19,679,956 and 19,427,331 issued, issuable and outstanding as of March 31, 2015 and December 31, 2014, respectively	20	19
Additional paid-in capital	6,644	5,763
Treasury Stock	(327)	(327)
Accumulated other comprehensive loss	(396)	(149)
Retained earnings	1,383	1,638
Total stockholders' equity	8,286	8,431
Total liabilities and stockholders' equity	$ 16,858	$ 16,439

XML

Organization and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1. Organization and Summary of Significant Accounting Policies

MEDITE Cancer Diagnostics, Inc., (“MDIT”, “MEDITE” or the “Company”) was incorporated in Delaware in December 1998.

These statements include the accounts of MEDITE Cancer Diagnostics, Inc., (former CytoCore, Inc., the “Company”, “we” and “us”) and its wholly owned subsidiaries, which consists of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany, MEDITE GmbH, Salzburg, Austria, MEDITE Lab Solutions, Inc. (formerly MEDITE Inc.), Orlando, USA, MEDITE sp. z o.o., Zilona-Gora, Poland and CytoGlobe, GmbH, Burgdorf, Germany.

In April 2014, the shareholders of the Company consummated a transaction in which 100% of the issued and outstanding shares of MEDITE Enterprise, Inc., were acquired by CytoCore, Inc. in exchange for the issuance by CytoCore, Inc., of 14,687,500 shares of its common stock to the shareholders of the Company. The result of this transaction was for the Company and its wholly owned subsidiaries to become wholly owned subsidiaries of CytoCore, Inc., a US public company. In addition, the shareholders of the Company became the majority owners of CytoCore, Inc., which resulted in the transaction being accounted for as a reverse merger, in which the financial statements of MEDITE Enterprise, Inc. and its subsidiaries became those of CytoCore, Inc., now MEDITE Cancer Diagnostics, Inc.         

MEDITE is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. By acquiring MEDITE the company changed from solely research operations to an operating company with 76 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry.

Consolidation, Basis of Presentation and Significant Estimates

The accompanying condensed consolidated financial statements for the periods ended March 31, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Cash and Cash Equivalents

The Company considers all cash on deposit and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10 yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through March 31, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.

XML

Preferred Stock and Warrants (Summary of Preferred Stock) (Detail)	Mar. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, shares issued	198,355	373,355
Preferred stock, shares outstanding	198,355	373,355
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	47,250	47,250
Preferred stock, shares outstanding	47,250	47,250
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	93,750	93,750
Preferred stock, shares outstanding	93,750	93,750
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	38,333	38,333
Preferred stock, shares outstanding	38,333	38,333
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	0	175,000
Preferred stock, shares outstanding	0	175,000
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	19,022	19,022
Preferred stock, shares outstanding	19,022	19,022

XML

Preferred Stock and Warrants (Tables)

3 Months Ended

Mar. 31, 2015

Stockholders' Equity (Deficit) [Abstract]

Summary of Company's Preferred Stock

A summary of the Company’s preferred stock as of March 31, 2015 and December 31, 2014 is as follows.

	March 31,		December 31,
	2015		2014
	(unaudited)
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		-		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		198,355		373,355

Summary of Preferred Stock Terms

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$10,303 per share
Conversion Rate:	0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$1,000 per share
Conversion Rate:	0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $530,038 and $520,665, respectively.

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$600 per share
Conversion Rate:	0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $154,288 and $151,413, respectively.

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$800.00 per share
Conversion Rate:	.0275—Liquidation Value divided by Conversion Price ($22.00/$800)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $568,177 and $558,173 respectively.

Warrants Outstanding

Warrants outstanding

					Weighted
		Weighted			Average
		Average		Aggregate	Remaining
	Options and	Exercise		Intrinsic	Contractual
	Warrants	Price		Value	Life (Years)
Outstanding at December 31, 2014	143,308	$	2.64	—	6.46
Granted	—	$	—	—	—
Exercised	—		—	—	—
Expired	—		—	—	—
Outstanding at December 31, 2013	143.308	$	2.64	—	6.46

XML

Preferred Stock and Warrants (Summary of Preferred Stock) (Parenthetical) (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%

XML

Organization and Summary of Significant Accounting Policies (Detail)	3 Months Ended
	Mar. 31, 2015
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	33 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years

XML

Reverse Merger

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Reverse Merger

Note 2. Reverse Merger

In January 2014, the Company and the previous owners of MEDITE Enterprise, Inc. entered into an agreement to merge with the former CytoCore, Inc. The merger required as a pre-requisite that among other items CytoCore settle certain outstanding payroll amounts in stock and that CytoCore complete a private placement with gross proceeds of a minimum of $2 million, which was later amended to $1.5 million. On April 3, 2014 CytoCore issued 697,234 shares of its common stock in satisfaction of approximately $1.6 million in outstanding accrued payroll. On April 4, 2014 the Company closed on a private placement in which it received gross proceeds of $1.5 million and issued 955,875 shares of its common stock. The merger closed on April 4, 2014 with the previous owners of MEDITE Enterprise, Inc. receiving 14,687,500 shares of the Company’s common stock. An additional 312,500 shares remain to be issued because certain conditions have been fulfilled in accordance with the agreement to complete the exchange for 100% of the issued and outstanding stock of MEDITE Enterprise, Inc. The consideration paid was determined based upon the number of shares outstanding from the former CytoCore, Inc. of approximately 3,502,700 common shares outstanding before the merger at $1.60 per share (the same price per share in the concurrent private placement noted above).

Because the owners of MEDITE Enterprise, Inc. received approximately 81.1% of the then issued and outstanding stock of the Company, the merger was treated as a reverse acquisition, in which for accounting purposes MEDITE Enterprise, Inc. acquired CytoCore, Inc. Therefore, the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2014 represents the financial results of MEDITE Enterprise, Inc. and subsidiaries only as the transaction did not occur until April 4, 2014.

Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

	In thousands
Assets acquired
Cash	$	1
Other current assets		12
Property and equipment		81
Trade names /trademarks		1,240
In-Process research and development		4,620
Goodwill		2,453
		8,407
Liabilities assumed
Accounts payable & accrued expenses		3,220
Related party advances		102
Loans payable		21
		3,343
Consideration paid in the form of common stock	$	5,064

The Company is treating the fair value assigned to trade names/trademarks as indefinite lived intangibles. The in process research and development covers four separate areas (a) breast pap device and related consumables (b) new biomarkers (c) a new stain and (d) the SoftKit. Until the Company either completes development or abandons such development, the in-process research and development costs are treated as indefinite lived intangible assets. If the Company is successful in these development projects, it expects the in-process research and development will be amortized over an approximate 15 year life.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred stock, shares issued	198,355	373,355
Preferred stock, shares outstanding	198,355	373,355
Preferred Stock, Liquidation Preference, Value	$ 1,121	$ 2,871
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000
Common Stock, Shares, Issued	19,679,956	19,427,331
Common Stock Issuable	19,679,956	19,427,331
Common Stock, Shares, Outstanding	19,679,956	19,427,331

XML

Organization and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Property Plant And Equipment Useful Life

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10 yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	May 20, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	Medite Cancer Diagnostics, Inc.
Entity Central Index Key	0000075439
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MDIT
Entity Common Stock, Shares Outstanding		19,679,956

XML

Reverse Merger (Tables)

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

	In thousands
Assets acquired
Cash	$	1
Other current assets		12
Property and equipment		81
Trade names /trademarks		1,240
In-Process research and development		4,620
Goodwill		2,453
		8,407
Liabilities assumed
Accounts payable & accrued expenses		3,220
Related party advances		102
Loans payable		21
		3,343
Consideration paid in the form of common stock	$	5,064

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net sales	$ 2,287	$ 2,734
Cost of revenues	1,369	1,474
Gross profit	918	1,260
Operating expenses
Depreciation and amortization expense	34	62
Research and development	262	199
Selling, general and administrative	807	629
Total operating expenses	1,103	890
Operating income (loss)	(185)	370
Other expenses
Interest expense	58	75
Other expenses	50	29
Total other expenses	108	104
Income (loss) before income taxes	(293)	266
Income tax expense (benefit)	(38)	47
Net income (loss)	(255)	219
Preferred dividend	(23)	0
Net income (loss) to common stockholders	(278)	219
Condensed statements of comprehensive income (loss)
Net income (loss)	(255)	219
Other comprehensive loss
Foreign currency translation adjustments	(247)	0
Comprehensive income (loss)	(502)	219
Earnings per share
Net income (loss) to common stockholders	$ (278)	$ 219
Basic and diluted earnings (loss) per share	$ (0.01)	$ 0.02
Weighted average basic and diluted shares outstanding	19,546,116	14,687,500

XML

Common Stock

3 Months Ended

Mar. 31, 2015

Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Common Stock

 Note 7. Common Stock

During the first quarter 2015, the Company issued 240,625 shares of unregistered stock to qualified individuals pursuant to exemptions from registration under Regulation D and Section 4(2) of the Securities Act of 1933 at 1.60 for proceeds of $385,000, net of 28,000 of issuance costs.

During the first quarter ended March 31, 2015, the Company issued 12,000 shares of common stock in a Series D Preferred Stock conversion as further discussed in Note 8.

XML

Related Party Advances

3 Months Ended

Mar. 31, 2015

Due to Related Parties, Current [Abstract]

Related Party Advances

Note 6. Related Party Advances

At December 31, 2014, the Company owed its then CFO and Chairman of the Board for prior advances of approximately $110,000. The CEO Michaela Ott together with the COO Michael Ott provided an additional $950,000 in a non-interest bearing short term advance at the end of the first quarter 2015. This advance is due on demand and at the date of the filing $620,000 was repaid to them, leaving an unpaid balance of $330,000.

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following tables show the breakdown of the Company’s operations and assets by region (in thousands):

	United States				Germany				Poland				Total
	March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014
Assets	$	9,307	$	9,387	$	7,449	$	6,989	$	102	$	63	$	16,858	$	16,439
Property & equipment, net		99		98		1,896		1,985		7		8		2,002		2,091
Intagible assets		8,313		8,313		-		-		-		-		8,313		8,313

	United States				Germany				Poland				Total
	March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014
Revenues	$	280	$	157	$	2,003	$	2,577	$	4	$	-	$	2,287	$	2,734
Net income (loss)		(163)		19		(76)		200		(16)		-		(255)		219

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2015

Inventory Disclosure [Abstract]

Schedule of Inventory

The following is a summary of the components of inventories (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Raw materials	$	1,208	$	1,229
Work in progress		27		33
Finished Goods		1,940		2,153
	$	3,175	$	3,415

XML

Segment Information

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Segment Information

Note 10. Segment Information

The Company operates in one operating segment. However, the Company has assets and operations in the United States, Germany and Poland. For the revenue and net income the March 31, 2014 numbers are the former MEDITE part only while the March 31, 2015 numbers are after the reverse merger and therefore combined with the former CytoCore, Inc. The influence by the significant chance of the currency exchange rate between USD and EURO since March 31, 2014 compared to March 31, 2015 is about $0.47 million. The following tables show the breakdown of the Company’s operations and assets by region (in thousands):

	United States				Germany				Poland				Total
	March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014		March 31, 2015		December 31, 2014
Assets	$	9,307	$	9,387	$	7,449	$	6,989	$	102	$	63	$	16,858	$	16,439
Property & equipment, net		99		98		1,896		1,985		7		8		2,002		2,091
Intagible assets		8,313		8,313		-		-		-		-		8,313		8,313

	United States				Germany				Poland				Total
	March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014		March 31, 2015		March 31, 2014
Revenues	$	280	$	157	$	2,003	$	2,577	$	4	$	-	$	2,287	$	2,734
Net income (loss)		(163)		19		(76)		200		(16)		-		(255)		219

XML

Preferred Stock and Warrants

3 Months Ended

Mar. 31, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Preferred Stock and Warrants

Note 8. Preferred Stock and Warrants

A summary of the Company’s preferred stock as of March 31, 2015 and December 31, 2014 is as follows.

	March 31,		December 31,
	2015		2014
	(unaudited)
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		-		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		198,355		373,355

As of March 31, 2015 and December 31, 2014, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation.

On February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. to convert $175,000 stated value of Series D Preferred Stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the Company’s common stock.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$10,303 per share
Conversion Rate:	0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$1,000 per share
Conversion Rate:	0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $530,038 and $520,665, respectively.

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$600 per share
Conversion Rate:	0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $154,288 and $151,413, respectively.

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$800.00 per share
Conversion Rate:	.0275—Liquidation Value divided by Conversion Price ($22.00/$800)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at March 31, 2015 and December 31, 2014 were $568,177 and $558,173 respectively.

Warrants outstanding

					Weighted
		Weighted			Average
		Average		Aggregate	Remaining
	Options and	Exercise		Intrinsic	Contractual
	Warrants	Price		Value	Life (Years)
Outstanding at December 31, 2014	143,308	$	2.64	—	6.46
Granted	—	$	—	—	—
Exercised	—		—	—	—
Expired	—		—	—	—
Outstanding at December 31, 2013	143.308	$	2.64	—	6.46

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 9. Commitments and Contingencies

The Company currently leases 13 vehicles for sales and service employees, delivery and other purposes with expirations ranging from May 2015 through February 2018. The current minimum monthly payment for these vehicle leases is approximately $6,024.

The Company has several operation leases for office, laboratory and manufacturing space. The Company’s operating lease for one of its German facilities can be cancelled by either party with a 3 months’ notice, its Poland facility can be terminated by either party with a six month notice. Monthly rent payments for the German and Poland facilities are Euro 4,000 ($4,513 as of March 31, 2015) and PLN 6,240 ($1,645 as of March 31, 2015) respectively. The Company’s laboratory facility in Chicago, IL terminates June 30, 2015 and requires monthly payments of $1,070. The Company also sublease its former Chicago laboratory facility for $3,916 per month. The lease for this facility terminates October 30, 2016 and require monthly rent payments of $4,270. The Company’s Orlando facility has escalating rents ranging from $2,345 to $2,563 per month and terminates July 31, 2018. The total aggregate monthly lease payments (net of the sublease) required on these leases is approximately $9,800.

In 2014, the Company became subject to a lawsuit brought by D&D Technologies, Inc. (“D&D”) in the state of New Jersey for breach of contract and breach of implied covenant of good faith that occurred in 2013 and prior by the former CytoCore for failure to pay for past contractual services. The original complaint was dismissed and then refiled by D&D. D&D is seeking damages over $86,000 plus equitable relief. In 2015, the Company and D&D engaged in settlement negotiations and at the time of this filing had verbally agreed to settle the matter for approximately $15,000, however, no formal written settlement has yet been entered into. This settlement has been accrued as of March 31, 2015 and included in account payable and accrued expenses on the accompanying condensed consolidated balance sheet.

XML

Organization and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Principle of Consolidation, Basis of Presentation and Significant Estimates

Consolidation, Basis of Presentation and Significant Estimates

The accompanying condensed consolidated financial statements for the periods ended March 31, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

Revenue Recognition

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all cash on deposit and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10 yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

Goodwill

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through March 31, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.

XML

Common Stock - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Class Of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	240,625
Share Price	$ 1.60
Stock Issued During Period, Value, New Issues	$ 385,000
Stock Issued During Period, Shares, Issued for Services	12,000
Stock Issued During Period, Value, Issued for Services	$ 28,000

XML

Long-term Debts and Lines of Credit (Tables)

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Outstanding note payable indebtedness

The Company’s outstanding note payable indebtedness was as follows as of (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Hannoversche Volksbank credit line #1	$	1,787	$	1,880
Hannoversche Volksbank credit line #2		409		465
Hannoversche Volksbank term loan #1		93		135
Hannoversche Volksbank term loan #2		74		81
Hannoversche Volksbank term loan #3		226		270
Ventana Medical Systems, Inc. Promissory Note		21		21
Debenture DZ Equity Partners Participation rights		814		912
	$	3,424	$	3,764

XML

Reverse Merger - (Estimated Purchase Price Allocation) (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Assets acquired
Cash	$ 1
Other current assets	12
Property and equipment	81
Trade names /trademarks	1,240
In-Process research and development	4,620
Goodwill	2,453	2,453
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	8,407
Liabilities assumed
Accounts payable & accrued expenses	3,220
Related party advances	102
Loans payable	21
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	3,343
Consideration paid in the form of common stock	$ 5,064

XML

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 Germany [Member] USD ($)	Mar. 31, 2015 Germany [Member] EUR (€)	Mar. 31, 2015 Poland [Member] USD ($)	Mar. 31, 2015 Poland [Member] PLN	Dec. 31, 2014 June Thirty Two Thousand Fifteen [Member] USD ($)	Mar. 31, 2015 October Thirty Two Thousand Sixteen [Member] USD ($)	Mar. 31, 2015 Maximum [Member] USD ($)	Mar. 31, 2015 Minimum [Member] USD ($)
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Net	$ 6,024
Operating Leases, Rent Expense, Minimum Rentals		4,513	4,000	1,645	6,240	1,070	4,270
Loss Contingency, Damages Paid, Value	86,000							2,563	2,345
Agreed To Legal Settlement	9,800							15,000
Operating Leases, Rent Expense, Sublease Rentals	$ 3,916

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (255)	$ 219
Adjustments to reconcile net income (loss) to cash (used in) provided by operating activities
Depreciation and amortization	34	62
Deferred income taxes	(66)	0
Changes in assets and liabilities:
Accounts receivable, net	158	228
Inventories	240	(374)
Prepaid expenses and other current assets	60	31
Accounts payable and accrued liabilities	(46)	(189)
Net cash (used in) provided by operating activities	125	(23)
Cash flows from investing activities
Purchases of equipment	(28)	(158)
Increase in other assets	(104)	0
Proceeds from related party advances	950	0
Net cash provided from (used in) investing activities	818	(158)
Cash flows from financing activities:
Net advances (repayments) on lines of credit and long-term debt	(340)	148
Proceeds from sale of common stock, net of issuance costs $28	357	0
Net cash provided by financing activities	17	148
Effect of exchange rates on cash and cash equivalents	(164)	0
Net increase (decrease) in cash and cash equivalents	796	(33)
Cash and cash equivalents at beginning of year	230	75
Cash and cash equivalents at end of the period	1,026	42
Supplemental disclosure of cash flow information:
Cash paid for interest	55	75
Cash paid for income taxes	28	0
Supplemental schedule of non-cash financing activity:
Conversion of preferred stock to common stock	$ 525	$ 0

XML

Long-term Debts and Lines of Credit

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Debt and Line of Credit

Note 5. Long-term Debts and Lines of Credit

The Company’s outstanding note payable indebtedness was as follows as of (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Hannoversche Volksbank credit line #1	$	1,787	$	1,880
Hannoversche Volksbank credit line #2		409		465
Hannoversche Volksbank term loan #1		93		135
Hannoversche Volksbank term loan #2		74		81
Hannoversche Volksbank term loan #3		226		270
Ventana Medical Systems, Inc. Promissory Note		21		21
Debenture DZ Equity Partners Participation rights		814		912
	$	3,424	$	3,764

In July 2006, MEDITE GmbH, Burgdorf, entered into a master line of credit agreement #1 with Hannoversche Volksbank. The line of credit was amended in 2012 and was later amended to increase the credit limit to Euro 1.8 million ($2.0 million as of March 31, 2015). In January 2015, the master credit line was reduced to Euro 1.6 million ($1.7 million as of March 31, 2015) and to be reduced by a further Euro 500,000 ($542,505 as of March 31, 2015) to Euro 1.1 million ($1.2 million as of March 31, 2015) effective June 1, 2015. Borrowings on the master line of credit agreement #1 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the company and defined in the agreement. Interest rates depending on the type of advance elected range from 3.77 – 8.00 % during the period ended March 31, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of MEDITE GmbH, Burgdorf, a mortgage on the buildings owned by the Company and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company.

In June 2012, CytoGlobe, GmbH, Burgdorf, entered into a line of credit agreement #2 with Hannoversche Volksbank. The line of credit granted a maximum borrowing authority of Euro 400,000 ($434,000 as of March 31, 2015). Borrowings on the master line of credit agreement #2 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the company and defined in the agreement. Interest rates depending on the type of advance elected range from 3.77 – 8.00 % during the period ended March 31, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of CytoGlobe GmbH, Burgdorf and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and the state of Lower Saxony (Germany) to support high-tech companies in the area.

In December 2006, MEDITE GmbH, Burgdorf, entered into a Euro 500,000 ($542,500 as of March 31, 2015) term loan agreement #1 with Hannoversche Volksbank with an interest rate of 3.4% per annum. The term loan has a maturity of September 2016 and requires semi-annual principal payments of approximately Euro 27,780 ($30,141 as of March 31, 2015) each. The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and also a mortgage on the property of the Company.

In June 2006, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($434,000 as of March 31, 2015) term loan #2 with Hannoversche Volksbank with an interest rate of 3.6 % per annum. The term loan has a maturity of June 2016, requires 18 semi-annual principal repayments of approximately Euro 22,220 ($24,109 as of March 31, 2015) each. The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and is collateralized by subordinated assignments of all of the receivables and inventories of MEDITE GmbH, Burgdorf and also has a subordinated pledge of share term life insurance policies.

In November 2008, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($434,000 as of March 31, 2015) term loan #3 with Hannoversche Volksbank with a variable interest rate of approximately 4.7% per annum as of December 31, 2014. The term loan has a maturity of December 31, 2018, and requires quarterly principal repayments of Euro 13,890 ($15,071 as of March 31, 2015) each. The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and is collateralized by a partial subordinated pledge of the receivables and inventory of MEDITE GmbH, Burgdorf.

In March 2009, the Company entered into a participation rights agreement in the form of a debenture with a mezzanine lender who advanced the Company up to Euro 1.5 million in two tranches of Euro 750,000 each. The first tranche was paid to the Company at closing with the second tranche being conditioned on MEDITE GmbH, Burgdorf and its subsidiaries hitting certain performance targets. Those targets were not met and the second tranche was never called. The debenture pays interest at the rate of 12.15% per annum and matures at December 31, 2016.

As of the date of filing, the remaining balance of approximately $21,000 on the note payable to Ventana Medical Systems, Inc. was in default. However, on February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. will accept $38,281 as payment in full for all outstanding principal and accrued interest. The $38,281 has been included in current portion of long-term debt on the consolidated balance sheet. As part of this agreement, Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the Company’s common stock. Prior to the execution of this agreement, the Company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.

XML

Reverse Merger - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Mar. 31, 2015	Apr. 04, 2014	Dec. 31, 2014	Apr. 03, 2014
Business Acquisition [Line Items]
Number of shares issued	240,625
Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement		$ 1.5	$ 1.5
Number of shares issued on acquisitions		14,687,500
Number of shares issued		955,875
Percentage of ownership interests acquired		100.00%
Reverse Acquisition Percentage Of Share Issued	81.10%
Business Combination Consideration Outstanding Shares		3,502,700
Business Combination Consideration Outstanding Shares Per Share		$ 1.60
In Process Research And Development Amortized Term		15 years
Medite Enterprises, inc [Member] | Accrued Payroll Settlement [Member]
Business Acquisition [Line Items]
Number of shares issued on acquisitions				697,234
Value of shares issued on acquisitions				1.6
Number of additional shares issued on acquisitions		312,500
Minimum [Member] | Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement			$ 2.0

XML

Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Parenthetical) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.50
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing March 31, 2001
Preferred stock, dividend date of commencement	Mar. 31, 2001
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 3.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing March 31, 2002
Preferred stock, dividend date of commencement	Mar. 31, 2002
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 22.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing May 31, 2002
Preferred stock, dividend date of commencement	May 31, 2002

XML

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

The following is a summary of the components of property and equipment (in thousands):

	March 31,		December 31,
	2015		2014
	(unaudited)
Land	$	208	$	233
Buildings		1,152		1,291
Machinery and equipment		492		529
Office furniture and equipment		237		265
Vehicles		92		103
Computer equipment		106		110
Construction in progress		510		559
Less: Accumulated depreciation		(795)		(999)
	$	2,002	$	2,091